1. Introduction {#sec1}
===============

Several autoimmune diseases (i.e., anti-phospholipid \[APL\] syndrome \[APS\] and systemic lupus erythematosus \[SLE\]) characterized by the production of APL autoantibodies are known to be associated with recurrent vascular thrombosis and/or obstetrical complications, including abortion, where APL autoantibodies are believed to play a causal role \[[@B1], [@B2]\]. Furthermore, in approximately 1-6% of healthy women, the presence of high levels of APL autoantibodies can be detected and can potentially affect physiological pregnancy \[[@B1], [@B2]\]. As well, we recently found that even moderately high levels of C-reactive protein (CRP), a classical biomarker of systemic inflammation, can help in recognizing pregnant women at increased risk for adverse outcomes \[[@B3]\], thus highlighting the pivotal effect that inflammation may have during pregnancy.

In APS and SLE, APL autoantibodies were shown to be associated with antibodies against apolipoprotein A-1 (anti-ApoA-1 IgG), the major fraction of high-density lipoproteins, and such association may be explained by a certain degree of cross-reactivity between APL and anti-ApoA-1 antibodies \[[@B3], [@B4]\]. The seropositivity for the latter antibodies is fairly prevalent in the general population (approximately 20%) and represents an independent predictor of death and acute cardiovascular events associated with vascular inflammation \[[@B4], [@B5]\]. Furthermore, experimental studies indicate that these antibodies can promote atherogenesis and atherothrombosis by acting on Toll-like receptors 2 and 4 \[[@B6]--[@B8]\]. Because of their possible cross-reactivity with APL antibodies and their proinflammatory effects, we hypothesized that anti-ApoA-1 IgG could jeopardize the balanced inflammatory process \[[@B4]\] involved in physiological pregnancy \[[@B9]\], promoting a proinflammatory systemic environment associated with the development of maternal complications and neonatal diseases \[[@B10]\]. Since the polyclonal anti-ApoA-1 IgG response in humans was shown to be oriented against the last *α*-helix of c-terminus part of native apoA-1 (amino acids: 220-242) \[[@B4], [@B11], [@B12]\], we aimed to determine the prevalence of both anti-ApoA-1 and anti-c-terminus apoA-1 (anti-Ac-terAA1) IgG and their possible relationship with threatened abortion (TA) in a general population of pregnant women.

2. Materials and Methods {#sec2}
========================

2.1. Study Population and Clinical Assessment {#sec2.1}
---------------------------------------------

As previously described \[[@B3]\], 380 consecutive outpatient pregnant women between the 24^th^ and 26^th^ gestational week (gestational age 23 weeks + 0 days--25 weeks + 6 days) aged 18 or older attending the Diabetology Unit of IRCCS Ospedale Policlinico San Martino (Genoa, Italy) were enrolled from October 2012 to November 2014. No other specific inclusion criteria than a pregnant status were established, while exclusion criteria consisted in clinical suspicion of an active infection or concurrent treatment with corticosteroids (*n* = 9), thus leaving 371 patients eligible for analyses. Methods for collection of serum samples as well as maternal adverse outcomes other than prevalent TA were already described elsewhere \[[@B3]\]. The Ethics Committee of the IRCCS Ospedale Policlinico San Martino (Genoa, Italy) approved this study, which was performed in accordance with the guidelines of the Declaration of Helsinki.

2.2. Study Endpoint Definition {#sec2.2}
------------------------------

The primary endpoint of our study was to evaluate the association of anti-ApoA-1 IgG and anti-Ac-terAA1 IgG with TA in this cohort of pregnant women. The secondary endpoint was to determine the prevalence of anti-ApoA-1 IgG and anti-Ac-terAA1 IgG in the enrolled subjects.

TA is an adverse maternal outcome that is defined based on the occurrence of vaginal bleeding with or without abdominal pain in the first 20 weeks of pregnancy, but diagnostic criteria for spontaneous abortion are not met \[[@B13]\].

2.3. Detection of Anti-ApoA-1 and Anti-Ac-terAA1 IgG and of C-Reactive Protein {#sec2.3}
------------------------------------------------------------------------------

Anti-ApoA-1 IgG serum levels were measured as previously described \[[@B6], [@B14]\]. In sum, MaxiSorp plates (Nunc) were coated with purified, human-derived delipidated apoA-1 or chemically engineered c-terAA1 \[[@B12]\] (20 *μ*g/mL; 50 *μ*L/well for both protein) for 1 hour at 37°C. Following three washes with phosphate buffered saline (PBS)/2% bovine serum albumin (BSA; 100 *μ*L/well), all wells were blocked for 1 hour with 2% BSA at 37°C. Samples were diluted 1 : 50 in PBS/2% BSA and incubated for 60 minutes. Other patient samples at the same dilution were also added to an uncoated well to assess individual nonspecific binding. After six further washes, 50 *μ*L/well of signal antibody (alkaline phosphatase-conjugated antihuman IgG; Sigma-Aldrich) diluted 1 : 1,000 in PBS/2% BSA solution was incubated for 1 hour at 37°C. After six more washes (150 *μ*L/well) with PBS/2% BSA solution, the phosphatase substrate p-nitrophenyl phosphate disodium (50 *μ*L/well; Sigma-Aldrich) dissolved in diethanolamine buffer (pH 9.8) was added. Each sample was tested in duplicate, and absorbance, determined as the optical density (OD) at 405 nm, was assessed after 20 minutes of incubation at 37°C (VersaMax, Molecular Devices). The corresponding nonspecific binding value was subtracted from the mean absorbance value for each sample. For anti-ApoA-1 IgG, the positivity cutoff was set at an OD value of 0.6 and 37% of the positive control value as described and validated in previous studies \[[@B6], [@B14]\]. OD values ranged from 0 to 1.78, and corresponding index values were between 0 and 99.2%. For anti-Ac-terAA1 IgG, OD values ranged between 0.21 and 1.45, and the index values ranged between 13 and 91%. By analogy, anti-Ac-terAA1 IgG seropositivity cutoff was set at the 97.5 centile of the distribution obtained on 160 healthy blood donors \[[@B15]\], which corresponded to an OD value above 0.5 and an index above 37% of the positive control. For both assays, at the seropositivity cutoffs, the interassay coefficients of variation were below 9% and the intra-assay CV below 5%.

Serum levels of CRP were measured by colorimetric enzyme-linked immunosorbent assay (ELISA) following the manufacturer\'s instructions (R&D Systems, Minneapolis, MN). The limit of detection was 15.625 pg/mL. Mean intra- and interassay coefficients of variation were \<8%.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Categorical data were presented as relative and absolute frequencies and compared with chi-square or Fisher\'s exact test, as appropriate, while continuous variables were shown as median and interquartile range (IQR) and their comparison was performed by nonparametric Mann--Whitney *U* test. The correlation between anti-ApoA-1 and anti-Ac-terAA1 IgG was calculated by Spearman\'s rank correlation test. The association between anti-ApoA-1 and anti-Ac-terAA1 IgG and TA was calculated by a linear regression analysis and expressed with 95% confidence interval (95% CI). The prognostic ability of the two autoantibodies towards the prediction of TA was measured by C-statistics, whose value was given with corresponding 95% CI. For the cutoffs of both anti-ApoA-1 and anti-Ac-terAA1 IgG, the corresponding sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively) were provided. Analyses were performed using IBM Statistical Package for Social Science (SPSS) for Windows, Version 25.0 (IBM Co., Armonk, NY) and MedCalc 12.5 (MedCalc Software, Ostend, Belgium).

3. Results {#sec3}
==========

3.1. Patients\' Characteristics {#sec3.1}
-------------------------------

Patients\' clinical characteristics are reported in [Table 1](#tab1){ref-type="table"}. Median age was 34 (31-37), and there was a substantial prevalence of the Caucasian race (90.5%). Median pre-pregnancy body mass index was 21.19 kg/m^2^ (19.80-23.57), while median CRP was 3.35 *μ*g/mL (1.62-8.28).

Most frequent comorbidities were gestational diabetes (11.9%), autoimmune diseases (6.7%), and thyroid disease (6.5%), while coagulopathies (including platelet disorders, such as gestational thrombocytopenia or idiopathic thrombocytopenic purpura) and polycystic ovary syndrome accounted for 1.9%. Among autoimmune diseases, Hashimoto thyroiditis was the most frequent one (4.9%) followed by SLE (0.5%), while Basedow\'s disease, Behçet syndrome, APS, chronic gastritis, and multiple sclerosis affected one woman each. Ten women (2.7%) experienced TA ([Table 1](#tab1){ref-type="table"}). Available adverse maternal outcomes (other than TA) are summarized in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

According to previously validated and predetermined cutoffs \[[@B6], [@B14], [@B15]\], 31 subjects (8.4%) were found positive for anti-ApoA-1 IgG and 82 (22.1%) for anti-Ac-terAA1 IgG. Despite this seropositivity prevalence difference, a positive correlation between anti-ApoA-1 and anti-Ac-terAA1 IgG was established (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). No correlation, however, was found for anti-ApoA-1 and anti-Ac-terAA1 IgG with systemic inflammation in terms of CRP (*r* = −0.094, *p* = 0.070 and *r* = −0.027, *p* = 0.600, respectively).

When comparing women based on positivity/negativity for anti-ApoA-1 and anti-Ac-terAA1 IgG (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}), no difference was found for comorbidities (with special reference to autoimmune diseases), therapies, and overall maternal adverse outcomes (Supplementary Tables [](#supplementary-material-1){ref-type="supplementary-material"}). However, TA occurrence was significantly increased among positive individuals as compared with negative ones for both autoantibodies (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}). With regard to ethnicity, anti-Ac-terAA1 IgG positive women were more frequently of ethnicity other than Caucasian ([Table 3](#tab3){ref-type="table"}), but such association was not found for anti-ApoA-1 IgG ([Table 2](#tab2){ref-type="table"}).

3.2. Anti-ApoA-1 IgG, Anti-Ac-terAA1 IgG, and Threatened Abortion Occurrence {#sec3.2}
----------------------------------------------------------------------------

Linear regression analyses showed a significant association between TA and anti-ApoA-1 IgG levels in the univariate model (*β* = 0.162, 95% CI 0.071-0.253, *p* \< 0.001, [Table 4](#tab4){ref-type="table"}). This result was confirmed also in the multivariate model when considering age and the presence of autoimmune diseases as potential confounders (*β* = 0.181, 95% CI 0.072-0.255, *p* \< 0.001, [Table 4](#tab4){ref-type="table"}). Similarly, anti-Ac-terAA1 IgG levels were associated with TA in the multivariate model (*β* = 0.179, 95% CI 0.067-0.240, *p* = 0.001, [Table 4](#tab4){ref-type="table"}).

These results were corroborated by C-statistics analyses, indicating that both anti-ApoA-1 and anti-Ac-terAA1 IgG serum levels during pregnancy displayed significant prognostic accuracy for TA (0.73, 95% CI 0.69-0.78, *p* \< 0.001 and 0.76, 95% CI 0.71-0.80, *p* = 0.007, Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, respectively). At the predetermined cutoff of anti-ApoA-1 IgG set at OD \>0.4 and an index \>37%, the test had a sensitivity of 100% and a specificity of 46.3% with a PPV of 4.9% and an NPV of 100%. According to C-statistics optimal cutoff set at OD \>0.7, anti-Ac-terAA1 IgG showed a sensitivity and a specificity of 70 and 85.3%, respectively, with a PPV of 11.7% and an NPV of 99.0%.

4. Discussion {#sec4}
=============

The main novelty of our study is that both anti-ApoA-1 and anti-Ac-terAA1 IgG are associated with TA in a general cohort of pregnant women. At the best of our knowledge, the role of these autoantibodies was not investigated before in gestation and represents a new field of research linking autoantibodies and pregnancy complications.

TA represents a serious pregnancy complication and is associated with an increased risk for adverse outcomes \[[@B16]\]. Abortion frequently occurs when fetus is affected by chromosomal abnormalities, but it may be also favored by several maternal factors, such as extreme weight (high or low) \[[@B17]\], older age, unhealthy lifestyle habits \[[@B18]\], and chronic illnesses, particularly autoimmune diseases (e.g., SLE) \[[@B19]\]. Both systemic and local inflammatory processes are believed to have a central role in abortion pathophysiology \[[@B20]\]. Since anti-ApoA-1 IgG were shown to promote a dose-dependent production of proinflammatory cytokines (interleukin \[IL\]-6, IL-8, and TNF-*α*, and matrix metalloproteinase-9) \[[@B6]\], an inflammatory link might be suspected between higher levels of these antibodies and TA. Therefore, as these cytokines stimulate T-helper 2 polarization \[[@B20]\] required for a successful pregnancy \[[@B21]\] and no correlation with CRP was found in the present study, other factors should be considered.

APL autoantibodies are a well-known risk factor for the development of obstetric and maternal complications \[[@B22]\]. Particularly, obstetric APS is the most frequent acquired risk factor for recurrent pregnancy loss \[[@B23]\]. In a recent study, APL positivity was associated with pregnancy adverse outcomes, independently of a confirmed diagnosis of APS and from treatment with aspirin or heparin \[[@B24]\]. According to recent studies, APL positivity may be more common than previously thought in the general population \[[@B22]\]. Further investigations, therefore, are warranted to explore the association of each antibody with pregnancy adverse outcomes.

Interestingly, women positive for anti-Ac-terAA1 IgG were more frequently of ethnicity other than Caucasian compared with negative ones, and such association was not found for anti-ApoA-1 IgG. By considering the results in our cohort, we may hypothesize that some ethnic groups show a predisposition to produce anti-Ac-terAA1 rather than anti-ApoA-1 antibodies. This hypothesis could be explained by the fact that the human polyclonal response is oriented against the c-ter part of apoA-1 \[[@B11], [@B12]\], as herein demonstrated by the larger seropositivity for anti-Ac-terAA1 IgG compared with anti-ApoA-1 IgG. Whether such difference may have clinical implication remains still elusive, and other population studies are needed to confirm these preliminary results.

We have to acknowledge some limitations in this observational study. First of all, the number of TAs is low in this cohort, so a further evaluation in a larger population is needed to confirm our results. Secondly, in this retrospective analysis, only women with full-term pregnancy were considered, while we do not have any data on women experiencing abortion to make a comparison and evaluate a possible role for abortion. Finally, data on lifestyle habits were not available, which might partially influence the analysis of pregnancy outcomes.

5. Conclusion {#sec5}
=============

In conclusion, high levels of anti-ApoA-1 IgG and anti-Ac-terAA1 during pregnancy are associated with TA confirming previous data on inflammation, when impaired, as a possible risk factor for abortion. Also, a different prevalence of anti-Ac-terAA1 IgG positivity emerged in our study according to ethnicity, which might represent a clinically relevant issue to be further investigated.

Although we found that anti-ApoA-1 IgG, a pro-inflammatory factor already validated in larger cohorts of patients suffering from cardiovascular disease, might negatively impact on gestation, larger studies are warranted to confirm these results.
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###### 

Supplementary Table 1: maternal adverse outcomes other than threatened abortion of the overall cohort. Supplementary Table 2: maternal adverse outcomes other than threatened abortion according to positivity/negativity for ApoA-1 IgG autoantibodies. Supplementary Table 3: maternal adverse outcomes other than threatened abortion according to positivity/negativity for Ac-terAA1 IgG autoantibodies. Supplementary Figure 1: Spearman\'s rank correlation between anti-ApoA-1 and anti-Ac-terAA1 IgG levels.

###### 

Click here for additional data file.

![C-statistics analysis for anti-apoA-1 IgG (a) and anti-Ac-terAA1 IgG (b) levels toward threatened abortion.](BMRI2020-9309121.001){#fig1}

###### 

Baseline characteristics of the overall cohort.

                                            *n* = 371
  ----------------------------------------- ------------------
  Demographics/biomarkers                   
   Age at enrollment (years)                34 (31-37)
   Ethnicity                                
    Caucasian, *n* (%)                      333 (90.5)
    Latin American, *n* (%)                 20 (5.4)
    African, *n* (%)                        6 (1.6)
    Indian, *n* (%)                         9 (2.4)
   BMI (kg/m^2^)                            21 (20-24)
   Weight gain at delivery (kg)             12 (10-15)
   CRP (*μ*g/mL)                            3.35 (1.62-8.28)
  Comorbidities                             
   Thyroid disease, *n* (%)                 24 (6.5)
   Hypertension, *n* (%)                    5 (1.3)
   PCOS, *n* (%)                            7 (1.9)
   Coagulopathies, *n* (%)                  7 (1.9)
   Autoimmune diseases, *n* (%)             25 (6.7)
    Hashimoto thyroiditis, *n* (%)          18 (4.9)
    Basedow\'s disease, *n* (%)             1 (0.3)
    SLE, *n* (%)                            2 (0.5)
    Behçet syndrome, *n* (%)                1 (0.3)
    APS, *n* (%)                            1 (0.3)
    Chronic gastritis, *n* (%)              1 (0.3)
    Multiple sclerosis, *n* (%)             1 (0.3)
   GDM, *n* (%)                             44 (11.9)
  Therapy                                   
   Thyroid hormone replacement, *n* (%)     21 (5.7)
   Aspirin, *n* (%)                         13 (3.5)
  Primary outcome                           
   Threatened abortion, *n* (%)             10 (2.7)
  Anti-ApoA-1 IgG                           
   Anti-ApoA-1 IgG positivity, *n* (%)      31 (8.4)
   Anti-ApoA-1, OD                          0.39 (0.30-0.51)
   Anti-Ac-terAA1 IgG positivity, *n* (%)   82 (22.1)
   Anti-Ac-terAA1 IgG, OD                   0.45 (0.36-0.58)

Data are presented as a number and percentage of all cases or as median and interquartile range (IQR). Ac-terAA1 IgG: anti-c-terminus apoA-1 autoantibody; Anti-apoA-1 IgG: apoliprotein A-1 autoantibody; APS: antiphospholipid syndrome; BMI: body mass index; CRP: C-reactive protein; GDM: gestational diabetes mellitus; OD: optical density; PCOS: polycystic ovary syndrome; SLE: systemic lupus erythematosus.

###### 

Baseline characteristics of the overall cohort according to positivity/negativity for anti-ApoA-1 IgG autoantibodies.

                                           Anti-ApoA-1 IgG negative (*n* = 340)   Anti-ApoA-1 IgG positive (*n* = 31)   *p*
  ---------------------------------------- -------------------------------------- ------------------------------------- -----------
  Demographics/biomarkers                                                                                               
   Age at enrollment (years)               34 (31-37)                             32 (29-36)                            0.082
   Ethnicity                                                                                                            0.355
    Caucasian, *n* (%)                     308 (90.9)                             25 (86.2)                             0.503
    Latin American, *n* (%)                18 (5.3)                               2 (6.9)                               0.665
    African, *n* (%)                       6 (1.8)                                0 (0)                                 1.000
    Indian, *n* (%)                        7 (2.0)                                2 (6.9)                               0.153
   BMI (kg/m^2^)                           21 (20-24)                             22 (20-26)                            0.303
   Weight gain at delivery (kg)            12 (10-15)                             13 (9-18)                             0.930
   CRP (*μ*g/mL)                           3.36 (1.57-8.65)                       2.72 (1.84-6.93)                      0.715
  Comorbidities                                                                                                         
   Thyroid disease, *n* (%)                22 (6.5)                               2 (6.5)                               1.000
   Hypertension, *n* (%)                   5 (1.5)                                0 (0)                                 1.000
   PCOS, *n* (%)                           7 (2.1)                                0 (0)                                 1.000
   Coagulopathies, *n* (%)                 7 (2.1)                                0 (0)                                 1.000
   Autoimmune diseases, *n* (%)            23 (6.8)                               2 (6.5)                               1.000
    Hashimoto thyroiditis, *n* (%)         16 (4.7)                               2 (6.5)                               0.655
    Basedow\'s diseases, *n* (%)           1 (0.3)                                0 (0)                                 1.000
    SLE, *n* (%)                           2 (0.6)                                0 (0)                                 1.000
    Behçet syndrome, *n* (%)               1 (0.3)                                0 (0)                                 1.000
    APS, *n* (%)                           1 (0.3)                                0 (0)                                 1.000
    Chronic gastritis, *n* (%)             1 (0.3)                                0 (0)                                 1.000
    Multiple sclerosis, *n* (%)            1 (0.3)                                0 (0)                                 1.000
   GDM, *n* (%)                            39 (11.5)                              5 (16.1)                              0.450
  Therapy                                                                                                               
   Thyroid hormone replacement, *n* (%)    19 (5.6)                               2 (6.5)                               0.691
   Aspirin, *n* (%)                        13 (3.8)                               0 (0)                                 1.000
  Pregnancy and delivery characteristics                                                                                
   Threatened abortion, *n* (%)            7 (2.1)                                3 (9.7)                               **0.042**

Data are presented as a number and percentage (%) of all cases or as median and interquartile range (IQR). *p* values have been calculated according to chi-square or Fisher\'s exact test or Mann--Whitney test, as appropriate, and referred to as comparisons between study groups. Statistically significant correlations have been highlighted in bold character. Anti-ApoA-1 IgG: apoliprotein A-1 autoantibody; APS: antiphospholipid syndrome; BMI: body mass index; CRP: C-reactive protein; GDM: gestational diabetes mellitus; PCOS: polycystic ovary syndrome; SLE: systemic lupus erythematosus.

###### 

Clinical characteristics of the cohort according to positivity/negativity for anti-c-terminus apoA-1 (Ac-terAA1) IgG autoantibodies.

                                          Anti-Ac-terAA1 IgG negative (*n* = 289)   Ac-terAA1 IgG positive (*n* = 82)   *p*
  --------------------------------------- ----------------------------------------- ----------------------------------- -----------
  Demographics/biomarkers                                                                                               
   Age at enrollment (years)              34 (31-37)                                33 (30-36)                          0.256
   Ethnicity                                                                                                            **0.005**
    Caucasian, *n* (%)                    267 (92.7)                                66 (82.5)                           **0.009**
    Latin American, *n* (%)               14 (4.9)                                  6 (7.5)                             0.402
    African, *n* (%)                      4 (1.4)                                   2 (2.5)                             0.615
    Indian, *n* (%)                       3 (1.0)                                   6 (7.5)                             **0.004**
   BMI (kg/m^2^)                          21 (20-24)                                21 (20-24)                          0.691
   Weight gain at delivery (kg)           12 (11-16)                                11 (9-15)                           0.209
  CRP (*μ*g/mL)                           3.32 (1.52-8.73)                          3.78 (1.85-7.29)                    0.936
  Comorbidities                                                                                                         
   Thyroid disease, *n* (%)               17 (5.9)                                  7 (8.5)                             0.444
   Hypertension, *n* (%)                  4 (1.4)                                   1 (1.2)                             1.000
   PCOS, *n* (%)                          6 (2.1)                                   1 (1.2)                             1.000
   Coagulopathies, *n* (%)                7 (2.4)                                   0 (0)                               0.356
   Autoimmune diseases, *n* (%)           18 (6.2)                                  7 (8.5)                             0.458
    Hashimoto thyroiditis, *n* (%)        12 (4.2)                                  6 (7.3)                             0.248
    Basedow\'s disease, *n* (%)           1 (0.3)                                   0 (0)                               1.000
    SLE, *n* (%)                          1 (0.3)                                   1 (1.2)                             0.394
    Behçet syndrome, *n* (%)              1 (0.3)                                   0 (0)                               1.000
    APS, *n* (%)                          1 (0.3)                                   0 (0)                               1.000
    Chronic gastritis, *n* (%)            1 (0.3)                                   0 (0)                               1.000
    Multiple sclerosis, *n* (%)           1 (0.3)                                   0 (0)                               1.000
   GDM                                    35 (12.2)                                 9 (11)                              0.764
  Therapy                                                                                                               
   Thyroid hormone replacement, *n* (%)   16 (5.5)                                  5 (6.1)                             0.791
   Aspirin, *n* (%)                       12 (4.2)                                  1 (1.2)                             0.313
  Primary outcome                                                                                                       
   Threatened abortion, *n* (%)           3 (1)                                     7 (8.5)                             **0.001**

Data are presented as a number and percentage (%) of all cases or as median and interquartile range (IQR). *p* values have been calculated according to chi-square or Fisher exact test or Mann--Whitney test, when appropriate, and referred to as comparisons between study groups. Statistically significant correlations have been highlighted in bold character. Anti-Ac-terAA1 IgG: anti-c-terminus ApoA-1 autoantibody; APS: antiphospholipid syndrome; BMI: body mass index; CRP: C-reactive protein; GDM: gestational diabetes mellitus; PCOS: polycystic ovary syndrome; SLE: systemic lupus erythematosus.

###### 

Linear regression analysis showing the association between anti-ApoA-1 IgG and anti-Ac-terAA1 IgG levels and threatened abortion.

                        Univariate model   Multivariate model                                       
  --------------------- ------------------ -------------------- ----------- -------- -------------- -------------
  Threatened abortion                                                                               
  Anti-apoA-1 IgG       0.162              0.071-0.253          **0.001**   0.181    0.072-0.255    **\<0.001**
  Age                                                                       0.009    −0.003-0.004   0.854
  Autoimmune diseases                                                       −0.048   −0.096-0.035   0.354
  Anti-Ac-terAA1 IgG    0.153              0.067-0.239          **0.001**   0.179    0.067-0.240    **0.001**
  Age                                                                       −0.004   −0.004-0.003   0.943
  Autoimmune diseases                                                       −0.048   −0.096-0.035   0.355

Statistically significant *p* values are displayed in bold characters. Anti-ApoA-1 IgG: apoliprotein A-1 autoantibody; Anti-Ac-terAA1 IgG: anti-c-terminus apoA-1 autoantibody; CI: confidence interval.
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